Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However, Johnson & Johnson...
Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is...
Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.
AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of $2.13. The reported earnings also exceeded the company’s guidance of $2.06-$2.10...
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease.This...
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over...
Recent earnings from these dividend-paying companies reflects their stability.
AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $14.92 billion...
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.